These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31528230)

  • 1. Comparison of Three Radiobiological Models in Stereotactic Body Radiotherapy for Non-Small Cell Lung Cancer.
    Lu JY; Lin Z; Lin PX; Huang BT
    J Cancer; 2019; 10(19):4655-4661. PubMed ID: 31528230
    [No Abstract]   [Full Text] [Related]  

  • 2. Revisiting the formalism of equivalent uniform dose based on the linear-quadratic and universal survival curve models in high-dose stereotactic body radiotherapy.
    Chan MKH; Chiang CL
    Strahlenther Onkol; 2021 Jul; 197(7):622-632. PubMed ID: 33245378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer.
    Guckenberger M; Klement RJ; Allgäuer M; Appold S; Dieckmann K; Ernst I; Ganswindt U; Holy R; Nestle U; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Andratschke N; Flentje M
    Radiother Oncol; 2013 Oct; 109(1):13-20. PubMed ID: 24183066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic body radiation therapy and 3-dimensional conformal radiotherapy for stage I non-small cell lung cancer: A pooled analysis of biological equivalent dose and local control.
    Mehta N; King CR; Agazaryan N; Steinberg M; Hua A; Lee P
    Pract Radiat Oncol; 2012; 2(4):288-295. PubMed ID: 24674167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges in radiobiological modeling: can we decide between LQ and LQ-L models based on reviewed clinical NSCLC treatment outcome data?
    Santiago A; Barczyk S; Jelen U; Engenhart-Cabillic R; Wittig A
    Radiat Oncol; 2016 May; 11():67. PubMed ID: 27154064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy.
    Park C; Papiez L; Zhang S; Story M; Timmerman RD
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):847-52. PubMed ID: 18262098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiobiological modeling of two stereotactic body radiotherapy schedules in patients with stage I peripheral non-small cell lung cancer.
    Huang BT; Lin Z; Lin PX; Lu JY; Chen CZ
    Oncotarget; 2016 Jun; 7(26):40746-40755. PubMed ID: 27203739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Control Probability Analysis for Single-Fraction Carbon-Ion Radiation Therapy of Early-Stage Non-small Cell Lung Cancer.
    Paz AE; Yamamoto N; Sakama M; Matsufuji N; Kanai T
    Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1551-1559. PubMed ID: 30076985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obtaining organ-specific radiobiological parameters from clinical data for radiation therapy planning of head and neck cancers.
    Quashie EE; Li XA; Prior P; Awan M; Schultz C; Tai A
    Phys Med Biol; 2023 Dec; 68(24):. PubMed ID: 37903437
    [No Abstract]   [Full Text] [Related]  

  • 10. Tumor control probability in hypofractionated radiotherapy as a function of total and hypoxic tumor volumes.
    Chvetsov AV; Hanin LG; Stewart RD; Zeng J; Rengan R; Lo SS
    Phys Med Biol; 2021 Jun; 66(12):. PubMed ID: 34030139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NTCP modelling of lung toxicity after SBRT comparing the universal survival curve and the linear quadratic model for fractionation correction.
    Wennberg BM; Baumann P; Gagliardi G; Nyman J; Drugge N; Hoyer M; Traberg A; Nilsson K; Morhed E; Ekberg L; Wittgren L; Lund JÅ; Levin N; Sederholm C; Lewensohn R; Lax I
    Acta Oncol; 2011 May; 50(4):518-27. PubMed ID: 21198416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Unified Dose Response Relationship to Predict High Dose Fractionation Response in the Lung Cancer Stereotactic Body Radiation Therapy.
    Kehwar TS; Chopra KL; Rai DV
    J Med Phys; 2017; 42(4):222-233. PubMed ID: 29296036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiobiological impact of dose calculation algorithms on biologically optimized IMRT lung stereotactic body radiation therapy plans.
    Liang X; Penagaricano J; Zheng D; Morrill S; Zhang X; Corry P; Griffin RJ; Han EY; Hardee M; Ratanatharathom V
    Radiat Oncol; 2016 Jan; 11():10. PubMed ID: 26800883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calculating the individualized fraction regime in stereotactic body radiotherapy for non-small cell lung cancer based on uncomplicated tumor control probability function.
    Lu JY; Lin PX; Huang BT
    Radiat Oncol; 2019 Jun; 14(1):111. PubMed ID: 31221159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A modified hypoxia-based TCP model to investigate the clinical outcome of stereotactic hypofractionated regimes for early stage non-small-cell lung cancer (NSCLC).
    Strigari L; Benassi M; Sarnelli A; Polico R; D'Andrea M
    Med Phys; 2012 Jul; 39(7):4502-14. PubMed ID: 22830782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of hyper- and hypofractionated radiation schemes with IMRT technique in small cell lung cancer: Clinical outcomes and the introduction of extended LQ and TCP models.
    Li QW; Qiu B; Wang B; Zhang J; Chen L; Zhou Y; Qin JK; Guo SP; Xie WH; Hui ZG; Liang Y; Guo JY; Wang H; Zhu M; Shen WT; Duan LY; Chen LK; Zhang L; Long H; Wang YM; Liu H
    Radiother Oncol; 2019 Jul; 136():98-105. PubMed ID: 31015136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies.
    van Leeuwen CM; Oei AL; Crezee J; Bel A; Franken NAP; Stalpers LJA; Kok HP
    Radiat Oncol; 2018 May; 13(1):96. PubMed ID: 29769103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The minimal FLASH sparing effect needed to compensate the increase of radiobiological damage due to hypofractionation for late-reacting tissues.
    Böhlen TT; Germond JF; Bourhis J; Bailat C; Bochud F; Moeckli R
    Med Phys; 2022 Dec; 49(12):7672-7682. PubMed ID: 35933554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative analysis of radiobiological models for cell surviving fractions at high doses.
    Andisheh B; Edgren M; Belkić D; Mavroidis P; Brahme A; Lind BK
    Technol Cancer Res Treat; 2013 Apr; 12(2):183-92. PubMed ID: 23098282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival and tumour control probability in tumours with heterogeneous oxygenation: a comparison between the linear-quadratic and the universal survival curve models for high doses.
    Lindblom E; Dasu A; Lax I; Toma-Dasu I
    Acta Oncol; 2014 Aug; 53(8):1035-40. PubMed ID: 24957551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.